Purdue Research Foundation, The Brigham and Women's Hospital Inc., the University of California Oakland and University of Utah have developed platinum complexes for the treatment of cyanide poisoning.

Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.

Amygdala Neurosciences Inc. has described aldehyde dehydrogenase-2 (ALDH2) inhibitors reported to be useful for the treatment of anxiety disorder, binge eating disorder, alcoholism, and amphetamine, cocaine, nicotine and opioid dependence.

RTI International has identified squaramide derivatives acting as cannabinoid CB1 receptor allosteric modulators reported to be useful for the treatment of obesity and substance abuse and dependence.

Recent studies have identified 70 oxygenized phosphatidylcholine (PC)-containing epoxy and hydroperoxide groups that are generated in the early phase of acetaminophen (APAP)-induced acute liver injury. In a new study, researchers from the University of Tokyo focused on arachidonate PC and assessed the role of liver-specific LPCAT3 (lysophospholipid acyltransferase 3) on APAP-induced acute liver injury in mice.

Idorsia Pharmaceuticals Ltd. researchers have prepared and tested new thiazoloaryl-methyl substituted cyclic hydrazine-N-carboxamide derivatives acting as orexin OX1 and OX2 receptor antagonists. They are reported to be useful for the treatment of substance abuse and dependence, anxiety, cognitive, sleep, eating and mood disorders.